About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

A 21 Day Pharmacokinetics Study in Papulopustular Rosacea

NCT02028286·2 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Maruho Co., Ltd.

Age

18–any

Sex

ALL

Healthy volunteers

Accepted

You may be eligible if

A diagnosis of papulopustular rosacea
Grade 3 or 4 on the 5-point Investigator Global Assessment scale
Presence of telangiectasia

You may not be if

steroid rosacea or subtype 3 (phymatous rosacea)
clinically significant abnormal findings that would interfere with study objective or risk to safety for the subject.
nodular rosacea (lesions greater than 5mm with more than 2 modules)

The record

StatusCompleted

PhasePhase 1

Taking part25

StartedJan 2014

UpdatedApr 14, 2014

Conditions

Papulopustular Rosacea

Where2

Frontage Clinical Services
Hackensack, New Jersey, United States
Derm Research
Austin, Texas, United States

Clareo Health | A 21 Day Pharmacokinetics Study in Papulopustular Rosacea